Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 1996

Effect of fluvastation on serum lipids in patients with essential hypertension

Judit Kaposci, Csaba Farsang, Gyula Pados, Katalin Detki, Zoltan Jarai, Janos Hollo, Zsuzsanna Sebestyen

Med Sci Monit 1996; 2(1): CR37-40 :: ID: 499518


Background: to assess the efficacy and safety of fluvastatin in the treatment of hypercholesterolaemia in hypertensive patients (WHO I-II).
Material/Methods: An 8 week low-lipid diet was started if the fasting total cholesterol (TC) level was equal to or higher than 6.5 mM and the triglyceride (TG) level was lower than 4.6 mM. After the dietary period fluvastatin treatment was started, (20 mg daily) if the LDL-C level was >4.1 mM. Blood pressure, heart rate, as well as TC, HDL-C (HDL2-C, HDL3-C), apo A1, apo B and TG were measured at 4, 8 and 12 weeks of treatment. The daily dose of fluvastatin was increased to 40 mg, if a satisfactory lowering of LDL-C (3.5 mM) was not obtained after 4 weeks of treatment. The number of patients included in the study was 49, mean age 57.0±10.7 years (X&plusm;SD), the blood pressure 142 ±16/85 ±11 mmHg (systolic/diastolic respectively). The antihypertensive treatment remained unchanged.
Results: Thirty-six patients completed the study (6 patients were withdrawn because of lack of compliance, 7 patients were withdrawn at the end of the dietary period, because of the normalisation of lipid levels). Fluvastatin significantly reduced the TC level (from 7.22±0.88 mM to 5.99±0.98 mM), LDL-C (from 5.13±0.78 mM to 3.95±0.88 mM) and Apo B (from 0.97±0.21 mM to 0.85±0.15 mM), but did not influence the levels of HDL-C, Apo A1 and TG. The diastolic blood pressure decreased significantly by the end of the dietary period. After the administration of fluvastatin, the systolic blood pressure decreased significantly. Only minor side effects were observed.
Conclusions: Fluvastatin proved to be an effective and well tolerated drug in the treatment of hypercholesterolaemia in hypertensive patients.

Keywords: essential hypertension, fluvastatin, hypercholesterolaemia

Add Comment 0 Comments


01 June 2024 : Editorial  

Editorial: Concerns as Highly Pathogenic Avian Influenza (HPAI) Virus of the H5N1 Subtype is Identified in Dairy Cows and Other Mammals

Dinah V. Parums

DOI: 10.12659/MSM.945315

Med Sci Monit 2024; 30:e945315


In Press

Clinical Research  

Anterior Plate-Supported Cannulated Screw Surgery for Ankle Arthrodesis: Clinical and Radiologic Results in...

Med Sci Monit In Press; DOI: 10.12659/MSM.944452  

Clinical Research  

Elevated Plasma Levels of Growth Arrest Specific 6 (Gas6) Protein in Severe Obesity: Implications for Adipo...

Med Sci Monit In Press; DOI: 10.12659/MSM.944462  

Database Analysis  

Systemic Immune-Inflammation Index (SII) as a Predictor of Short-Term Mortality Risk in Sepsis-Associated A...

Med Sci Monit In Press; DOI: 10.12659/MSM.943414  

Clinical Research  

Morphological Variations of the Nasopalatine Canal in the North Cyprus Population: A Cone Beam Computed Tom...

Med Sci Monit In Press; DOI: 10.12659/MSM.944868  

Most Viewed Current Articles

17 Jan 2024 : Review article   2,131,100

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


14 Dec 2022 : Clinical Research   1,555,090

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


16 May 2023 : Clinical Research   690,471

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial   50,389

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750